SRI 31215 (TFA) 是 Matriptase/Hepsin/HGFA三重抑制剂，模拟 HAI-1/2（HGF活化的内源性抑制剂）的活性。 SRI 31215 对 matriptase、hepsin 和 HGFA 具有有效的抑制活性，IC₅₀ 值分别为 0.69 μM、0.65 μM 和 0.30 μM。SRI 31215 可用于癌症研究。

SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation). SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC 50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer.

Solid

IC50: 0.69 μM (matriptase); 0.65 μM (hepsin); 0.30 μM (HGFA)

SRI 31215 (TFA) has potent activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively.
SRI 31215 (10 μM) inhibits the proteolytic activation of pro-HGF.
SRI 31215 (10 μM, 30 min) inhibits fibroblast-induced HGF/MET signaling in tumor cells.
SRI 31215 (10 μM, 24 h) inhibits fibroblast-induced epithelial mesenchymal transition (EMT) and migration in tumor cells.
SRI 31215 (10 μM) overcomes the resistance to EGFR inhibitors mediated by autocrine HGF/MET signaling in colon cancer cells.
SRI31215 (10 μM, 72 h) averts fibroblast-mediated resistance to EGFRi-induced apoptosis. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moistur In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

[1]. Owusu BY, et al. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget. 2016 May 17;7(20):29492-506.

In Vitro: DMSO : 125 mg/mL (234.26 mM; Need ultrasonic)配制储备液